Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Centogene NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CNTG
Nasdaq
8731
https://www.centogene.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Centogene NV
CENTOGENE Receives Nasdaq Non-Compliance Notice
- Apr 2nd, 2024 8:30 pm
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
- Mar 19th, 2024 10:30 am
CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency
- Feb 29th, 2024 10:00 pm
CENTOGENE Explores Strategic Alternatives
- Feb 28th, 2024 11:30 am
CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing
- Feb 28th, 2024 11:30 am
CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration
- Jan 25th, 2024 11:30 am
CENTOGENE Receives French Research Tax Credit Accreditation
- Jan 24th, 2024 11:30 am
CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics
- Jan 23rd, 2024 11:30 am
CENTOGENE Announces Preliminary Full Year 2023 Revenue
- Jan 18th, 2024 11:30 am
CENTOGENE Announces Voting Results of Extraordinary General Meeting
- Dec 19th, 2023 11:30 am
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
- Dec 13th, 2023 11:30 am
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction
- Nov 28th, 2023 11:30 am
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism
- Nov 14th, 2023 1:30 pm
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering
- Oct 10th, 2023 10:30 am
CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Sep 11th, 2023 12:30 pm
CENTOGENE Reports First Half 2023 Financial Results
- Sep 7th, 2023 9:00 pm
CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients
- Sep 1st, 2023 12:00 pm
CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
- Aug 31st, 2023 8:30 pm
CENTOGENE to Participate in Upcoming Conferences in August
- Aug 7th, 2023 10:30 am
CENTOGENE Regains Compliance With Nasdaq Listing Requirements
- Jul 14th, 2023 10:30 am
Scroll